bristol myers - Search News

News

Bristol Myers Squibb Cuts Full-Year Adjusted View

The Wall Street Journal on MSN · 15h

Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations

Bristol Myers Squibb trimmed its full-year adjusted earnings view as it reported lower second-quarter earnings due to a charge related to its BioNTech partnership.

Barron's on MSN · 1d

Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.

Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs expire in the coming years.

Reuters on MSN · 1d

Bristol Myers tops revenue expectations on strength of older drugs, shares fall

Bristol Myers Squibb posted much better-than-expected second-quarter results on Thursday on strong sales of its best-selling brands, but failed to convince investors that newer products could drive future growth and shares fell nearly 5%.

30mon MSN

Bristol-Myers Squibb shares snapped six-session losing streak

Myers Squibb (NYSE:BMY) shares inched up on Friday after six consecutive sessions of fall. The stock was up 2.2% at $44.24.

1d

Why Bristol-Myers Squibb (BMY) Stock Is Trading Lower Today

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 4.2% in the afternoon session after the company ...

23h

Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors

Shares of Bristol Myers Squibb Co. BMY slid 5.81% to $43.31 Thursday, on what proved to be an all-around dismal trading ...

2h

Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields

Bristol-Myers Squibb remains a compelling Buy despite the market's over-reaction to the industry and macro headwinds. Learn ...

8h

Should You Be Impressed By Bristol-Myers Squibb Company's (NYSE:BMY) ROE?

Many investors are still learning about the various metrics that can be useful when analysing a stock. This article ...

Fierce Pharma1d

Bristol Myers touts commercial execution, reckons with recent clinical setbacks

Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

3h

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Investors weren't impressed with Bristol-Myers Squibb Company's (BMY) Q2 2025 results, with the stock down by 5.8% after ...

3don MSN

Bristol Myers, Bain Capital form new company to develop immunology drugs

Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on developing ...

BioPharma Dive3d

Bain leads $300M investment in startup built on Bristol Myers immune drugs

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

1don MSN

Bristol-Myers delivers double beat and raises full-year sales forecast

Shares of Bristol-Myers Squibb (NYSE:BMY) popped 2.4% premarket on Thursday after the pharma giant beat Street forecasts with ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results